ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1,2,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
1,3,Headache,Headaches NEC,Headaches,Nerv,N
1,4,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
1,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
1,6,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1,7,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
2,4,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
2,5,Headache,Headaches NEC,Headaches,Nerv,N
2,6,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2,7,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
2,8,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
2,9,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
3,1,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
3,2,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
5,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
5,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
5,3,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
5,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
5,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
6,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
6,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
7,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
8,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
8,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
9,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
10,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
10,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
11,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
11,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
12,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
13,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
13,2,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
13,3,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
13,4,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
13,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
13,6,Scleral discolouration,"Scleral structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
14,1,Child-Pugh-Turcotte score increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
14,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
14,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
15,1,Urticarial vasculitis,Urticarias,Angioedema and urticaria,Skin,N
16,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
17,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
18,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
18,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
19,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
20,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
20,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
20,3,Headache,Headaches NEC,Headaches,Nerv,N
20,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
20,5,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
20,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
21,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
22,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
22,2,Nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
23,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
24,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
24,2,Nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
24,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
25,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
25,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
25,3,Negative thoughts,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
26,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
27,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
27,2,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
28,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
29,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
29,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
29,3,Biliary dilatation,Structural and other bile duct disorders,Bile duct disorders,Hepat,N
29,4,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
29,5,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
29,6,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
29,7,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
29,8,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
29,9,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
29,10,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
29,11,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
29,12,Mucosal haemorrhage,Mucosal findings abnormal,General system disorders NEC,Genrl,N
29,13,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
29,14,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
29,15,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
29,16,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
29,17,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
30,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
30,2,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
30,3,Model for end stage liver disease score increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
31,1,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
32,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
33,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
34,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
34,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
34,3,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,1,Cholangitis,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
35,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
36,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
37,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
38,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
38,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
38,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
38,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
38,5,Remission not achieved,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
39,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
40,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
40,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
40,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
40,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
40,5,Remission not achieved,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
41,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
41,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
41,3,Biliary dilatation,Structural and other bile duct disorders,Bile duct disorders,Hepat,N
41,4,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
41,5,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
41,6,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
41,7,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
41,8,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
41,9,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
41,10,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
41,11,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
41,12,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
41,13,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
41,14,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
41,15,Mucosal haemorrhage,Mucosal findings abnormal,General system disorders NEC,Genrl,N
41,16,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
41,17,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
41,18,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
41,19,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
41,20,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
42,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
42,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
43,1,Small cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
44,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
45,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
46,1,Liver transplant,Hepatic therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
46,2,Transplantation complication,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,Y
47,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
48,1,Transplantation complication,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,Y
49,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
50,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
50,2,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
50,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
50,4,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
51,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
51,2,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
51,3,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
52,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
52,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
53,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
53,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
53,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
53,4,Primary biliary cholangitis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
54,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
54,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
55,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
56,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
56,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
56,3,Transplant evaluation,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
57,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
58,1,Colostomy,Large intestine therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
58,2,Food refusal,Appetite disorders,Appetite and general nutritional disorders,Metab,Y
58,3,Gastrointestinal procedural complication,Gastrointestinal and hepatobiliary procedural complications,Procedural related injuries and complications NEC,Inj&P,N
58,4,Haemorrhoid operation,Anorectal therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
58,5,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
58,6,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
59,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
59,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
60,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
60,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
61,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
62,1,Carbuncle,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
62,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
62,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
63,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
64,1,Lung operation,Bronchial and pulmonary therapeutic procedures,Respiratory tract therapeutic procedures,Surg,N
64,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
65,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
65,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
65,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
66,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
66,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
67,1,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
67,2,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
68,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
69,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
69,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
69,3,Scratch,Skin injuries NEC,Injuries NEC,Inj&P,N
70,1,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
70,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
71,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
72,1,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,Y
73,1,Oesophageal varices haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
74,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
75,1,Hepatocellular carcinoma,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,Y
76,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,Y
77,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
78,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,Y
79,1,Pneumonia aspiration,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
80,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
81,1,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
81,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
82,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
83,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
84,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
85,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
85,2,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
85,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
85,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
86,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
86,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
86,3,Positive airway pressure therapy,Respiratory tract therapeutic procedures NEC,Respiratory tract therapeutic procedures,Surg,N
86,4,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
87,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
87,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
88,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
89,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
89,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
89,3,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
89,4,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
89,5,Sleep terror,Parasomnias,Sleep disorders and disturbances,Psych,N
90,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
90,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
91,1,Back disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
91,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
92,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
92,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
92,3,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
93,1,Blood bilirubin abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
93,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
94,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
94,2,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
95,1,Decreased activity,Asthenic conditions,General system disorders NEC,Genrl,N
95,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
95,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
96,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
96,2,Migraine,Migraine headaches,Headaches,Nerv,N
97,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
97,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
97,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
97,4,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
97,5,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
98,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
98,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
98,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
99,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
99,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
99,3,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
100,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
100,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
101,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
102,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
102,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
103,1,Headache,Headaches NEC,Headaches,Nerv,N
104,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
104,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
104,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
105,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
105,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
106,1,Deafness,Hearing losses,Hearing disorders,Ear,N
106,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
107,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
107,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
107,3,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
107,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
108,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
109,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
109,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
110,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
111,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
112,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
112,2,Myopathy,Myopathies,Muscle disorders,Musc,N
112,3,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
113,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
114,1,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
114,2,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
114,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
114,4,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
115,1,Chemotherapy,Chemotherapies,Therapeutic procedures and supportive care NEC,Surg,N
115,2,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
116,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
116,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
117,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
117,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
118,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
119,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
120,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
121,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
122,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
123,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
124,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
125,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
126,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
127,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
127,2,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
127,3,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
127,4,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
127,5,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
128,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
128,2,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
129,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
129,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
130,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
131,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
132,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
133,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
134,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
134,2,Furuncle,Staphylococcal infections,Bacterial infectious disorders,Infec,N
134,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
134,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
134,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
134,6,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
135,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
135,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
136,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
137,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
137,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
138,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
139,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
140,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
141,1,Deafness,Hearing losses,Hearing disorders,Ear,N
142,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
143,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
143,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
144,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
145,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
145,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
146,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
146,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
146,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
147,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
148,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
148,2,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
148,3,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
148,4,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
149,1,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
149,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
150,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
150,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
151,1,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
151,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
152,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
153,1,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
154,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
155,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
156,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
157,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
158,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
159,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
160,1,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
160,2,Migraine,Migraine headaches,Headaches,Nerv,N
160,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
161,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
162,1,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
162,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
162,3,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
163,1,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
163,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
163,3,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
163,4,Migraine,Migraine headaches,Headaches,Nerv,N
163,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
163,6,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
164,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
164,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
165,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
165,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
165,3,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
166,1,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
167,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
167,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
168,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
169,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
170,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
170,2,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
170,3,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
171,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
172,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
172,2,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
172,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
172,4,Knee arthroplasty,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
172,5,Physiotherapy,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
173,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
174,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
174,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
175,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
176,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
176,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
176,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
176,4,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
176,5,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
176,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
176,7,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
176,8,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
176,9,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
177,1,Critical illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
178,1,Aortic aneurysm,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
178,2,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
179,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
180,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
180,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
181,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
181,2,Cardiac dysfunction,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
181,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
182,1,Hepatic fibrosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
182,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
183,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
184,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
185,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
185,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
186,1,Coronavirus infection,Coronavirus infections,Viral infectious disorders,Infec,N
187,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
188,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
188,2,Polymyalgia rheumatica,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
188,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
188,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
189,1,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
189,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
189,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
189,4,Refusal of treatment by patient,Social issues NEC,Lifestyle issues,SocCi,N
189,5,Sensitisation,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
189,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
190,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
191,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
191,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
192,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
193,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
193,2,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
194,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
194,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
195,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
196,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
197,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
198,1,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
198,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
199,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
200,1,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
200,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
200,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
201,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
202,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
203,1,Bedridden,Disability issues,Lifestyle issues,SocCi,N
203,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
204,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
205,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
205,2,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
205,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
205,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
206,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
207,1,Thyroxine increased,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
207,2,Tri-iodothyronine increased,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
208,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
209,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
210,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
211,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
212,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
213,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
214,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
215,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
215,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
216,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
216,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
216,3,Scratch,Skin injuries NEC,Injuries NEC,Inj&P,N
217,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
218,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
218,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
218,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
219,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
220,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
220,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
221,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
222,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
222,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
222,3,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
223,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
223,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
223,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
223,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
223,5,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
224,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
225,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
226,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
226,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
227,1,Autoimmune hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
228,1,Autoimmune hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
229,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
230,1,Bedridden,Disability issues,Lifestyle issues,SocCi,N
230,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
231,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
231,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
231,3,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
231,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
231,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
232,1,Cardiac pacemaker insertion,Cardiac device therapeutic procedures,Cardiac therapeutic procedures,Surg,N
232,2,Complication associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
233,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
233,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
233,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
234,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
235,1,Gastric varices haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
236,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
236,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
236,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
237,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
237,2,Oesophageal carcinoma,Oesophageal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
238,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
239,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
240,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
240,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
241,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
241,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
242,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
242,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
243,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
244,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
245,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
245,2,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
245,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
245,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
246,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
247,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
247,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
247,3,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
248,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
248,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
249,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
249,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
250,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
251,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
252,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
252,2,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
253,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
253,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
253,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
254,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
255,1,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
256,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
257,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
258,1,Cholecystitis infective,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
258,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
258,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
259,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
260,1,Hip arthroplasty,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
260,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
261,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
262,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
262,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
262,3,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
262,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
262,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
263,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
263,2,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
264,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
265,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
265,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
265,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
266,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
266,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
266,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
267,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
267,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
267,3,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
268,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
268,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
268,3,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
268,4,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
268,5,Model for end stage liver disease score increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
268,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
268,7,Varices oesophageal,Oesophageal varices,Gastrointestinal vascular conditions,Gastr,N
269,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
270,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
270,2,Therapy cessation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
271,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
272,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
272,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
272,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
272,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
273,1,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
273,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
273,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
